Piper Sandler has upgraded Supernus Pharmaceuticals Inc (SUPN) from Neutral to Overweight as of October 8, 2025. The stock is currently priced at $46.01.
This upgrade underscores a more optimistic view on Supernus Pharmaceuticals’ future prospects. The change in analyst sentiment may signal improved fundamentals, better-than-expected business performance, or increased confidence in the company's strategic direction.
Based in Rockville, Maryland, Supernus Pharmaceuticals specializes in developing and commercializing products for central nervous system diseases. The company’s diverse portfolio includes treatments for attention-deficit hyperactivity disorder (ADHD), Parkinson’s disease, postpartum depression, epilepsy, and migraines, among others. Its notable products include Qelbree, GOCOVRI, and ONAPGO, an infusion device for treating motor fluctuations in advanced Parkinson’s patients.
As of November 20, 2025, Supernus boasts a market capitalization of $2.6 billion and a trailing twelve-month EPS of -0.34. Looking ahead, the company is expected to report earnings on August 3, 2026, with an EPS estimate of $0.59 and revenue expectations of $212.0 million.
Analyst consensus as of November 1, 2025, indicates a majority positive outlook, with 4 Strong Buy, 6 Buy, and 2 Hold ratings among 12 total analysts. Recent actions over the last 90 days include Piper Sandler's upgrade and a maintenance of Overweight by Cantor Fitzgerald, reflecting a generally favorable view of the company's trajectory.